CTLA4
Jiangsu Hengrui Licenses CStone Pharmaceuticals' Anti-CTLA-4 Candidate in Greater China
The drug, CS1002, is being studied in melanoma, hepatocellular carcinoma, and microsatellite instability high or mismatch repair deficient tumors.
Oncolytic Viruses May Help Cancer Patients Overcome Resistance to Immunotherapy, Research Shows
Premium
A new study suggests that using rotavirus in combination with immune checkpoint blockade therapy could give oncologists a new way to treat pediatric cancers.
Response to Combined Immunotherapy in Melanoma Associated With TMB, Cell-Free DNA, ctDNA
A prospective study in 35 advanced melanoma patients found that response to combined Yervoy and Opdivo was correlated with the three markers.
Researchers Explore Variety of Response Markers in Melanoma Study of Combo Checkpoint Inhibitors
Premium
Using samples from different points in patients' treatment, researchers employed a variety of tools, including NanoString's GeoMx DSP, to explore potential response markers.